Zynerba Pharmaceuticals (NASDAQ: ZYNE)
Some price data may be temporarily unavailable.
Zynerba Pharmaceuticals Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Zynerba Pharmaceuticals Company Info
Zynerba Pharmaceuticals, Inc. engages in the provision of pharmaceutically-produced transdermal cannabinoid therapies. It focuses on the research and development of rare and near-rare neuropsychiatric conditions. The firm offers the Zygel product, which is formulated as a permeation-enhanced gel for transdermal delivery. The company was founded by Audra L. Stinchcomb on January 31, 2007 and is headquartered in Devon, PA.
News & Analysis
Face the Facts: The CBD Hype Train Has Derailed
This is yet another reminder that all next-big-thing investments need time to mature.
Why Zynerba Pharmaceuticals Stock Is Crashing Today
Investors appear to be worried about potential safety issues with its cannabinoid gel.
Here's Why Zynerba Pharmaceuticals Lost 21.8% in July
The stock cooled off along with its cannabis-based peers.
Here's Why Zynerba Pharmaceuticals Stock Soared 356% in the First Half of the Year
The marijuana craze has hit this clinical-stage pharmaceutical company.
5 Best Biotech Stocks of 2019 So Far
These biotech stocks have at least quadrupled in just over six months this year.
These Are the Only 15 Pot Stocks That Rose in the Second Quarter
Only around 1 in 4 marijuana stocks ended the second quarter higher.
The Best Marijuana Stocks in the First Half of 2019
Seven cannabis stocks doubled, and nearly two-thirds of all pot stocks ended the period higher.
Why Zynerba Pharmaceuticals Stock Is Skyrocketing Today
A new patent is generating excitement among investors for this clinical-stage biotech stock.
Valuation
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.